Afficher la notice abrégée

dc.contributor.authorUreña Paniego, Clara Amanda
dc.contributor.authorMontero Vílchez, Trinidad
dc.contributor.authorSanabria de la Torre, Raquel 
dc.contributor.authorSoto Moreno, Alberto
dc.contributor.authorMolina Leyva, Alejandro 
dc.contributor.authorArias Santiago, Salvador Antonio 
dc.date.accessioned2024-09-25T11:39:23Z
dc.date.available2024-09-25T11:39:23Z
dc.date.issued2023-01-20
dc.identifier.citationUreña-Paniego, C.; Montero-Vílchez, T.; Sanabria-de-la-Torre, R.; Soto-Moreno, A.; Molina-Leyva, A.; Arias-Santiago, S. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study. Int. J. Environ. Res. Public Health 2023, 20, 1918. https://doi.org/10.3390/ijerph20031918es_ES
dc.identifier.urihttps://hdl.handle.net/10481/95091
dc.description.abstractAtopic dermatitis (AD) is a chronic inflammatory skin disease presenting as xerosis, eczema and intense pruritus. These symptoms negatively impact patients’ quality of life. However, the effect of AD on sexual function and sleep quality and how treatment with dupilumab could modify them have not been explored in depth. The aim of this study is to assess the effects of dupilumab on sexual and sleep quality in patients with AD. For that purpose, an observational prospective study was designed. Patients were evaluated at baseline and after 16 weeks of dupilumab treatment. Disease severity was assessed by Eczema Area and Severity (EASI) and SCORing Atopic Dermatitis index (SCORAD). Sexual function was evaluated using validated questionnaires, for men via the International Index of Erectile Dysfunction 5 (IIEF-5) and for women via the Female Sexual Function Index (FSFI). Sleep impairment was recorded through Pittsburgh Sleep Quality Index (PSQI). Thirtytwo patients, with a mean age of 30.53 ± 14.48 years old, were included. Regarding sex, 59.8% (20) were female. Most patients had a severe disease reflected in a mean basal EASI of 23.24 ± 6.74 and a SCORAD of 54.07 ± 13.89. Clinical scores improved after dupilumab treatment. At baseline, 47.37% women presented sexual dysfunction and 66.67% men had erectile dysfunction. FSFI improved from 23.51 to 27.93 points (p = 0.008) after dupilumab. Desire, arousal, satisfaction and pain were the components with great improvement. Women with a great improvement in FSFI showed greater clinical results and increased quality of life. At first, 96.9% (31/32) of participants presented with poor sleep quality. After treatment with dupilumab, sleep quality was enhanced and PSQI scores decreased from 12.8 points at baseline to 7.73 points (p < 0.001). In conclusion, dupilumab is associated with reduced sexual dysfunction, mainly in women, and sleep quality.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAtopic dermatitis es_ES
dc.subjectDupilumabes_ES
dc.subjectSexual health es_ES
dc.titleImprovement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Studyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/ijerph20031918
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 4.0 Internacional